Galidesivir Limits Rift Valley Fever Virus Infection and Disease in Syrian Golden Hamsters

Overview

Journal Antiviral Res

Publisher Elsevier

Date 2018 Jun 5

PMID 29864447

Citations 31

Authors

Jonna B Westover

Amanda Mathis

Ray Taylor

Luci Wandersee

Kevin W Bailey

Eric J Sefing

Brady T Hickerson

Kie-Hoon Jung

William P Sheridan

Brian B Gowen

Affiliations

Soon will be listed here.

Abstract

Rift Valley fever virus (RVFV) is a mosquito-borne pathogen endemic to sub-Saharan Africa and the Arabian Peninsula. There are no approved antiviral therapies or vaccines available to treat or prevent severe disease associated with RVFV infection in humans. The adenosine analog, galidesivir (BCX4430), is a broad-spectrum antiviral drug candidate with in vitro antiviral potency (EC of less than 50 μM) in more than 20 different viruses across eight different virus families. Here we report on the activity of galidesivir in the hamster model of peracute RVFV infection. Intramuscular and intraperitoneal treatments effectively limited systemic RVFV (strain ZH501) infection as demonstrated by significantly improved survival outcomes and the absence of infectious virus in the spleen and the majority of the serum, brain, and liver samples collected from infected animals. Our findings support the further development of galidesivir as an antiviral therapy for use in treating severe RVFV infection, and possibly other related phleboviral diseases.

Citing Articles

Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control.

Wang S, Li W, Wang Z, Yang W, Li E, Xia X Signal Transduct Target Ther. 2024; 9(1):223.

PMID: 39256346 PMC: 11412324. DOI: 10.1038/s41392-024-01917-x.

Nucleotide and nucleoside-based drugs: past, present, and future.

Abdullah Al Awadh A Saudi J Biol Sci. 2022; 29(12):103481.

PMID: 36389209 PMC: 9641258. DOI: 10.1016/j.sjbs.2022.103481.

Significant perspectives on various viral infections targeted antiviral drugs and vaccines including COVID-19 pandemicity.

Arumugam G, Damodharan K, Doble M, Thennarasu S Mol Biomed. 2022; 3(1):21.

PMID: 35838929 PMC: 9283561. DOI: 10.1186/s43556-022-00078-z.

Structural Modifications and Biological Evaluations of Rift Valley Fever Virus Inhibitors Identified from Chemical Library Screening.

Islam K, Carlsson M, Enquist P, Qian W, Marttila M, Strand M ACS Omega. 2022; 7(8):6854-6868.

PMID: 35252679 PMC: 8892858. DOI: 10.1021/acsomega.1c06513.

Nucleosides and emerging viruses: A new story.

Roy V, Agrofoglio L Drug Discov Today. 2022; 27(7):1945-1953.

PMID: 35189369 PMC: 8856764. DOI: 10.1016/j.drudis.2022.02.013.

References

Ikegami T, Makino S . The pathogenesis of Rift Valley fever. Viruses. 2011; 3(5):493-519. PMC: 3111045. DOI: 10.3390/v3050493. View

Turell M, Dohm D, Mores C, Terracina L, Wallette Jr D, Hribar L . Potential for North American mosquitoes to transmit Rift Valley fever virus. J Am Mosq Control Assoc. 2009; 24(4):502-7. DOI: 10.2987/08-5791.1. View

Julander J, Siddharthan V, Evans J, Taylor R, Tolbert K, Apuli C . Efficacy of the broad-spectrum antiviral compound BCX4430 against Zika virus in cell culture and in a mouse model. Antiviral Res. 2016; 137:14-22. PMC: 5215849. DOI: 10.1016/j.antiviral.2016.11.003. View

Gowen B, Wong M, Jung K, Sanders A, Mendenhall M, Bailey K . In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob Agents Chemother. 2007; 51(9):3168-76. PMC: 2043187. DOI: 10.1128/AAC.00356-07. View

Scharton D, Bailey K, Vest Z, Westover J, Kumaki Y, van Wettere A . Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment. Antiviral Res. 2014; 104:84-92. PMC: 3975078. DOI: 10.1016/j.antiviral.2014.01.016. View

McElroy A, Nichol S . Rift Valley fever virus inhibits a pro-inflammatory response in experimentally infected human monocyte derived macrophages and a pro-inflammatory cytokine response may be associated with patient survival during natural infection. Virology. 2011; 422(1):6-12. PMC: 6487494. DOI: 10.1016/j.virol.2011.09.023. View

Eyer L, Zouharova D, Sirmarova J, Fojtikova M, Stefanik M, Haviernik J . Antiviral activity of the adenosine analogue BCX4430 against West Nile virus and tick-borne flaviviruses. Antiviral Res. 2017; 142:63-67. DOI: 10.1016/j.antiviral.2017.03.012. View

Golnar A, Kading R, Hamer G . Quantifying the potential pathways and locations of Rift Valley fever virus entry into the United States. Transbound Emerg Dis. 2017; 65(1):85-95. DOI: 10.1111/tbed.12608. View

Kortekaas J . One Health approach to Rift Valley fever vaccine development. Antiviral Res. 2014; 106:24-32. DOI: 10.1016/j.antiviral.2014.03.008. View

10.

Scharton D, Van Wettere A, Bailey K, Vest Z, Westover J, Siddharthan V . Rift Valley fever virus infection in golden Syrian hamsters. PLoS One. 2015; 10(1):e0116722. PMC: 4301868. DOI: 10.1371/journal.pone.0116722. View

11.

Warren T, Wells J, Panchal R, Stuthman K, Garza N, Van Tongeren S . Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature. 2014; 508(7496):402-5. PMC: 7095208. DOI: 10.1038/nature13027. View

12.

Taylor R, Kotian P, Warren T, Panchal R, Bavari S, Julander J . BCX4430 - A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease. J Infect Public Health. 2016; 9(3):220-6. PMC: 4937725. DOI: 10.1016/j.jiph.2016.04.002. View

13.

Julander J, Bantia S, Taubenheim B, Minning D, Kotian P, Morrey J . BCX4430, a novel nucleoside analog, effectively treats yellow fever in a Hamster model. Antimicrob Agents Chemother. 2014; 58(11):6607-14. PMC: 4249364. DOI: 10.1128/AAC.03368-14. View

14.

Smith D, Bird B, Lewis B, Johnston S, McCarthy S, Keeney A . Development of a novel nonhuman primate model for Rift Valley fever. J Virol. 2011; 86(4):2109-20. PMC: 3302397. DOI: 10.1128/JVI.06190-11. View

15.

Hartman A, Powell D, Bethel L, Caroline A, Schmid R, Oury T . Aerosolized rift valley fever virus causes fatal encephalitis in african green monkeys and common marmosets. J Virol. 2013; 88(4):2235-45. PMC: 3911574. DOI: 10.1128/JVI.02341-13. View

16.

Bird B, Ksiazek T, Nichol S, Maclachlan N . Rift Valley fever virus. J Am Vet Med Assoc. 2009; 234(7):883-93. DOI: 10.2460/javma.234.7.883. View